LON:HVO hVIVO (HVO) Share Price, News & Analysis GBX 10 +0.25 (+2.56%) As of 11:50 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesBuy This Stock About hVIVO Stock (LON:HVO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get hVIVO alerts:Sign Up Key Stats Today's Range 9.50▼ 10.2050-Day Range 8.70▼ 1852-Week Range 6.50▼ 30.50Volume932,438 shsAverage Volume3.23 million shsMarket Capitalization£70.76 millionP/E Ratio4.12Dividend Yield1.10%Price TargetGBX 35Consensus RatingBuy Company Overview hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. Read More hVIVO Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreHVO MarketRank™: hVIVO scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatinghVIVO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragehVIVO has only been the subject of 1 research reports in the past 90 days.Read more about hVIVO's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of hVIVO is 4.12, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.97.Price to Earnings Ratio vs. SectorThe P/E ratio of hVIVO is 4.12, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.07.Price to Book Value per Share RatiohVIVO has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for HVO. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldhVIVO pays a meaningful dividend of 1.10%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthhVIVO does not have a long track record of dividend growth.Read more about hVIVO's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for HVO. News and Social Media1.3 / 5News Sentiment0.30 News SentimenthVIVO has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for hVIVO this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, hVIVO insiders have not sold or bought any company stock.Percentage Held by Insiders14.03% of the stock of hVIVO is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.90% of the stock of hVIVO is held by institutions.Read more about hVIVO's insider trading history. Receive HVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for hVIVO and its competitors with MarketBeat's FREE daily newsletter. Email Address HVO Stock News HeadlinesDon’t get caught short! Here’s how to identify penny stocks with long-term potentialJune 28, 2025 | msn.comShould I buy penny stock hVIVO after its fall to 10p?June 3, 2025 | msn.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 25 at 2:00 AM | American Alternative (Ad)After falling 46% in a day, hVIVO’s become a penny stock… again!June 2, 2025 | msn.comhVIVO Shares Plunge After Contract Cancellation, Profit WarningMay 30, 2025 | marketwatch.comhVIVO announces annual report and upcoming AGMMay 13, 2025 | investing.comLooking for UK shares to buy? This 19p small-cap down 5% today may be worth consideringJanuary 29, 2025 | msn.comIf he had $1m today, here’s how this Warren Buffett disciple would build wealthJanuary 26, 2025 | msn.comSee More Headlines HVO Stock Analysis - Frequently Asked Questions How have HVO shares performed this year? hVIVO's stock was trading at GBX 20.50 at the start of the year. Since then, HVO shares have decreased by 51.2% and is now trading at GBX 10. How were hVIVO's earnings last quarter? hVIVO plc (LON:HVO) posted its earnings results on Thursday, April, 10th. The company reported $1.69 earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a trailing twelve-month return on equity of 47.93%. How do I buy shares of hVIVO? Shares of HVO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of hVIVO own? Based on aggregate information from My MarketBeat watchlists, some other companies that hVIVO investors own include ValiRx (VAL), boohoo group (BOO), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), IQE (IQE) and Rolls-Royce Holdings plc (RR). Company Calendar Last Earnings4/10/2025Today7/25/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:HVO Previous SymbolLON:RVG CIKN/A Webhvivo.com Phone+44-20-77561300FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for hVIVOGBX 35 High Price TargetGBX 35 Low Price TargetGBX 35 Potential Upside/Downside+250.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)GBX 2.42 Trailing P/E Ratio4.12 Forward P/E Ratio6.45 P/E GrowthN/ANet Income£17.84 million Net Margins25.96% Pretax MarginN/A Return on Equity47.93% Return on Assets11.97% Debt Debt-to-Equity Ratio33.86 Current Ratio1.61 Quick Ratio1.16 Sales & Book Value Annual Sales£68.74 million Price / Sales1.03 Cash FlowGBX 2.03 per share Price / Cash Flow4.94 Book ValueGBX 5.56 per share Price / Book1.80Miscellaneous Outstanding Shares707,586,880Free FloatN/AMarket Cap£70.76 million OptionableNot Optionable Beta0.97 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (LON:HVO) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding hVIVO plc Please log in to your account or sign up in order to add this asset to your watchlist. Share hVIVO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.